SANOFI PASTEUR

Your trusted vaccine resource

**When thinking of back-to-school season, think Sanofi Pasteur. Sanofi Pasteur offers a broad portfolio of vaccines for your patients.[1-5]**

**Pentacel®**
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine

Only Pentacel vaccine is FDA approved as a 4-dose DTaP[a], IPV[b], and Hib[c] series.[6,7]

**Adacel®**
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed

The first and only Tdap[e] vaccine approved for repeat vaccination. Indicated to be given to patients as early as 10 years of age through 64.[10]

**Quadracel®**
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine

Together with Pentacel vaccine, you can help complete the childhood immunization schedule using only 2 products.[6-8]

**Fluzone® Quadrivalent**
INFLUENZA VACCINE

Committed to supporting your influenza vaccination efforts.

**Menactra®**
Meningococcal (Groups A,C,Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

The first and only MenACWY[d] that is FDA approved for both the 1st and 2nd doses—with no reconstitution required.[9]

[a] DTaP = Diphtheria, tetanus, and acellular pertussis.
[b] IPV = Inactivated poliovirus.
[c] Hib = *Haemophilus influenzae* type b.
[d] MenACWY = Quadrivalent meningococcal conjugate vaccine.
[e] Tdap = Tetanus, diphtheria, and acellular pertussis.

**PLEASE CONSIDER THE SANOFI PASTEUR PORTFOLIO FOR THIS BACK-TO-SCHOOL SEASON. PRODUCTS ARE AVAILABLE THROUGH YOUR VACCINE SUPPLIER.**

## INDICATION FOR PENTACEL AND QUADRACEL VACCINES

Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to *H influenzae* type b. Pentacel vaccine is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to fifth birthday).

Quadracel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis. A single dose of Quadracel vaccine is approved for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received 4 doses of Pentacel vaccine and/or DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed).

## INDICATION FOR MENACTRA VACCINE

Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent *N meningitidis* serogroup B disease.

## INDICATION FOR ADACEL VACCINE

Adacel vaccine is indicated for active booster immunization against tetanus, diphtheria, and pertussis. Adacel is approved for use in individuals 10 through 64 years of age.

## INDICATION FOR FLUZONE QUADRIVALENT VACCINE

Fluzone Quadrivalent vaccine is indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Fluzone Quadrivalent vaccine is approved for use in persons 6 months of age and older.

**Please see the Important Safety Information on page 2 and the full Prescribing Information for Pentacel, Quadracel, Menactra, Adacel and Fluzone Quadrivalent vaccines.**

SANOFI PASTEUR

Your trusted vaccine resource

## IMPORTANT SAFETY INFORMATION FOR PENTACEL AND QUADRACEL VACCINES

Contraindications to vaccination with Pentacel or Quadracel vaccine include: a severe allergic reaction (eg, anaphylaxis) to any ingredient of the vaccine, or following any other diphtheria toxoid-, tetanus toxoid-, pertussis antigen-containing vaccine, inactivated poliovirus vaccine, or *Haemophilus influenzae* type b vaccine (Pentacel vaccine only); encephalopathy within 7 days after a previous dose of a pertussis antigen-containing vaccine with no other identifiable cause; or a progressive neurologic disorder.

Carefully consider benefits and risks before administering Pentacel or Quadracel vaccine to persons with a history of: fever ≥105°F, hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis antigen-containing vaccine; seizures within 3 days after a previous pertussis antigen-containing vaccine; Guillain-Barré syndrome occurring within 6 weeks following receipt of a prior vaccine containing tetanus toxoid; or adverse events after a previous dose of Pentacel or Quadracel vaccine or receipt of any other tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine.

For infants and children with a history of previous seizures, an antipyretic may be administered (in the dosage recommended in its prescribing information) at the time of vaccination with Pentacel vaccine and for the next 24 hours.

Apnea following intramuscular vaccination has been observed in some infants born prematurely.

The most common local and systemic adverse reactions to Pentacel vaccine include erythema, swelling, and tenderness at the injection site; fever, fussiness, and abnormal crying. The most common local and systemic adverse reactions to Quadracel vaccine include pain, erythema, and edema at the injection site; myalgia, malaise, and headache. Other adverse reactions may occur.

Vaccination with Pentacel or Quadracel vaccine may not protect all individuals.

## IMPORTANT SAFETY INFORMATION FOR MENACTRA VACCINE

Menactra vaccine is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid-, or $CRM_{197}$- containing vaccine, or to any component of the vaccine.

Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. GBS has been reported in temporal relationship following administration of Menactra vaccine. The decision to give Menactra vaccine should be based on careful consideration of the potential benefits and risks.

Syncope (fainting) can occur in association with administration of injectable vaccines, including Menactra vaccine. Procedures should be in place to prevent falling injury and manage syncopal reactions.

The most common local and systemic adverse reactions to Menactra vaccine include pain, redness, and swelling at the injection site and appetite loss (all age groups); induration at the injection site and diarrhea (all age groups except infants); irritability and drowsiness (infants and children); abnormal crying, vomiting, and fever (infants); headache, fatigue, malaise, and arthralgia (adolescents and adults). Other adverse reactions may occur. Vaccination with Menactra vaccine may not protect all individuals.

SANOFI PASTEUR. Discovery Drive. Swiftwater, Pennsylvania 18370. www.sanofi.us
SAUS.MIS.19.06.3580  6/19

## IMPORTANT SAFETY INFORMATION FOR ADACEL VACCINE

Adacel vaccine is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any other tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of Adacel; or encephalopathy within 7 days after a previous dose of a pertussis antigen-containing vaccine with no other identifiable cause.

For one presentation of Adacel, the tip caps of the prefilled syringes may contain natural rubber latex, which may cause allergic reactions in latex-sensitive individuals. The vial stopper is not made with natural rubber latex.

If Guillain-Barré syndrome or brachial neuritis has occurred within 6 weeks following previous vaccination with a tetanus toxoid-containing vaccine, if progressive or unstable neurologic disorders exist, or if adverse events have occurred in temporal relation to receipt of pertussis antigen-containing vaccine, the decision to give Adacel should be based on careful consideration of the potential benefits and risks.

Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of tetanus toxoid-containing vaccine should not receive Adacel unless at least 10 years have elapsed since the last dose of tetanus toxoid-containing vaccine.

Syncope (fainting) can occur in association with administration of injectable vaccines, including Adacel. Procedures should be in place to prevent falling injury and manage syncopal reactions.

After the first and second dose of Adacel, the most frequently reported solicited reactions were pain, swelling, and erythema at the injection site; headache, body ache or muscle weakness, tiredness, myalgia, and malaise.

Other adverse reactions may occur. Vaccination with Adacel may not protect all individuals.

## IMPORTANT SAFETY INFORMATION FOR FLUZONE QUADRIVALENT VACCINE

Fluzone Quadrivalent vaccine should not be administered to anyone who has had a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone Quadrivalent vaccine should be based on careful consideration of the potential benefits and risks.

The most common local adverse reactions to Fluzone Quadrivalent vaccine include pain at the injection site (all ages) and erythema and swelling at the injection site (in children). The most common systemic reactions include myalgia, malaise, and headache (irritability, abnormal crying, drowsiness, appetite loss, vomiting, and fever in young children). Other adverse reactions may occur. Vaccination with Fluzone Quadrivalent vaccine may not protect all individuals.

**References: 1.** Access to Medicine Foundation. Access to vaccines index 2017. https://accesstovaccinesindex.org/media/atvi/2017-Access-to-Vaccines-Index.pdf. Updated March 2017. Accessed February 7, 2019. **2.** GlaxoSmithKline. Products. https://www.gskdirect.com/gsk/en/USD/RootCategory/c/1. Accessed February 7, 2019. **3.** Merck & Co. Inc. Product list A-Z. https://www.merck.com/product/home.html. Accessed February 7, 2019. **4.** Pfizer. Pfizer products. https://www.pfizerpro.com/pfizer-products. Accessed February 7, 2019. **5.** Sanofi. Sanofi (2017) annual report on form 20-F 2017. https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/S-Z/Sanofi-20-F-2017-EN-PDF-e-accessible_01.pdf. Accessed February 7, 2019. **6.** Pentacel vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc. **7.** Centers for Disease Control and Prevention (CDC). Recommended child and adolescent immunization schedule for aged 18 years or younger, United States, 2019. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. Accessed February 7, 2019. **8.** Quadracel vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc. **9.** Menactra vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc. **10.** Adacel vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.

**Please see the full Prescribing Information for Pentacel, Quadracel, Menactra, Adacel and Fluzone Quadrivalent vaccines.**